1.	Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: REO 016, NCT00861627
2.	Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: REO 020, NCT00984464
3.	A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: REO 021, NCT00998192
4.	A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: REO 017, NCT00998322
5.	Phase II Randomized Study of Weekly Paclitaxel With Versus Without Wild-Type Reovirus in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0186H, GOG-0186H, NCT01199263
6.	Phase II Randomized Study of Carboplatin and Paclitaxel With Versus Without Wild-Type Reovirus (Reolysin®) as First-Line Treatment in Patients With Recurrent or Metastatic Pancreatic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: OSU-10045, OSU-10045, 8601, NCT01280058
7.	Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: I209, NCT01619813
8.	Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: I210, NCT01622543
9.	A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: I213, NCT01656538
10.	Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00234, OSU-07022, U01CA076576, CDR0000584038, 07022, 7853, 2007 C0028, NCT00602277
11.	Phase I Study of Wild-Type Reovirus in Pediatric Patients With Relapsed or Refractory Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: COG-ADVL1014, ADVL1014, NCT01240538
12.	Phase I Study of Wild-Type Reovirus in Patients With Relapsed or Refractory Multiple Myeloma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: OSU-11148, 11148, 9030, NCT01533194